Searchable abstracts of presentations at key conferences in endocrinology

ea0007oc13 | Development and growth | BES2004

A novel GH variant (Ile179Met) exhibits a decreased ability to activate the ERK pathway

Lewis M , Horan M , Millar D , Easter T , Fryklund L , Gregory J , Valle C , Canete R , Ulied A , Procter A , Cooper D , Scanlon M

The pituitary-expressed growth hormone 1 gene was screened for mutation in a group of 74 Spanish children with familial short stature resulting in the identification of a novel Ile179Met missense mutation. Variant and wild-type GH were expressed in insect cells and functional studies were performed. The Ile179Met variant was shown to exhibit a similar degree of resistance to proteolysis as wild-type GH, indicating that the introduction of Met does not cause significant ...

ea0052p14 | (1) | UKINETS2017

Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

Horsch D , Kulke MH , Caplin M , Anthony L , Bergsland E , Oberg K , Warner R , Kunz P , Pulido E Grande , Valle J , Dillon J , Lapuerta P , Banks P , Jackson S , Pavel M

Background: The phase III, placebo-controlled, randomized TELESTAR study evaluated efficacy and safety of telotristat ethyl (TE) in patients (pts) with diarrhoea (≥4 bowel movements (BMs)/day) due to carcinoid syndrome (CS) inadequately controlled by somatostatin analogs (SSAs). TE, a tryptophan hydroxylase inhibitor, decreases peripheral serotonin levels. As add-on treatment to SSAs, TE 250 mg 3x/day (tid) and TE 500 mg tid significantly reduced BM frequency (P...

ea0046oc3 | (1) | UKINETS2016

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Horsch D , Kulke M , Caplin M , Anthony L , Bergsland E , Oberg K , Welin S , Warner R , Lombard-Bohas C , Kunz P , Valle J , Fleming D , Lapuerta P , Banks P , Pavel M

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...